Reverting TIL Exhaustion to Generate a TIL Product with More Stemness-Like T-Cells & a Broader T-Cell Repertoire to Improve Clinical Outcome
Time: 1:30 pm
day: Conference Day Two - Track A - PM
Details:
- Mapping T-cell specificities against tumor associated and HPV-derived antigens in TIL therapy products in cervical cancer
- Key strategies for ex vivo enrichment of tumor-reactive TILs including reinvigorating exhausted TILs and selective expansion
- Arming T-cells against oxidative stress preserving killing functionality in the hostile tumor microenvironment
